Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Aug 27, 2026, 13:15Praveen Kaudlay: Advancing Hemophilia Care in Davanagere
-
Aug 27, 2026, 13:13Wolfgang Miesbach: Potential Transmission of Haemorrhagic Risk Through Blood Transfusion
-
Aug 27, 2026, 13:09Jignesh Patel: Can Edoxaban and Rivaroxaban Be Prescribed for Breastfeeding Mothers?
-
Aug 27, 2026, 13:09Nouran Abu-Obaid: Anticoagulation for New-Onset Atrial Fibrillation in Critical Illness
-
Aug 27, 2026, 13:04Nabil Chakfe: Carotid Stent Design and Antiplatelet Therapy Influence Thrombosis Risk
-
Aug 27, 2026, 13:01Lukong Hubert Shalanyuy: New Research on Thromboplastin Reagents and PT/INR Reliability
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities